Compare · BCDA vs BNTX
BCDA vs BNTX
Side-by-side comparison of BioCardia Inc. (BCDA) and BioNTech SE (BNTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BCDA and BNTX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $22.66B, about 1594.8x BCDA ($14.2M).
- BNTX has been more active in the news (9 items in the past 4 weeks vs 5 for BCDA).
- BNTX has more recent analyst coverage (25 ratings vs 1 for BCDA).
- Company
- BioCardia Inc.
- BioNTech SE
- Price
- $0.92-1.18%
- $87.69-2.80%
- Market cap
- $14.2M
- $22.66B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 5
- 9
- Recent ratings
- 1
- 25
BioCardia Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Latest BCDA
- SEC Form 8-K filed by BioCardia Inc.
- BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting
- BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
- President and CEO Altman Peter bought $1,030 worth of shares (1,000 units at $1.03), increasing direct ownership by 0.26% to 384,885 units (SEC Form 4)
- President and CEO Altman Peter bought $1,995 worth of shares (1,900 units at $1.05), increasing direct ownership by 0.50% to 383,885 units (SEC Form 4)
- BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
- BioCardia Inc. filed SEC Form 8-K: Other Events
- BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest BNTX
- SEC Form 6-K filed by BioNTech SE
- BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
- SEC Form 4 filed by BioNTech SE
- Argus initiated coverage on BioNTech
- SEC Form 4 filed by BioNTech SE
- SEC Form 4 filed by BioNTech SE
- Chief Executive Officer Sahin Ugur sold $3,301,068 worth of Ordinary Shares (34,000 units at $97.09) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 180,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,480,659 worth of Ordinary Shares (66,000 units at $98.19) as part of a pre-agreed trading plan, decreasing direct ownership by 24% to 214,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,012,500 worth of Ordinary Shares (61,000 units at $98.57) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 280,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,842,742 worth of Ordinary Shares (69,000 units at $99.17) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 341,209 units (SEC Form 4)